Line 57: | Line 57: | ||
{axis:"Anticancer E. coli health risk",value:0.467}, | {axis:"Anticancer E. coli health risk",value:0.467}, | ||
{axis:"Manageability of health risks",value:0.46}, | {axis:"Manageability of health risks",value:0.46}, | ||
− | {axis:"Anticancer E. coli | + | {axis:"Anticancer E. coli environmental risk",value:0.39}, |
{axis:"Manageability of environmental risks",value:0.517}, | {axis:"Manageability of environmental risks",value:0.517}, | ||
{axis:"Commercial development of RNAi classifiers",value:0.598}, | {axis:"Commercial development of RNAi classifiers",value:0.598}, | ||
{axis:"Benefits of RNAi classifiers",value:0.571}, | {axis:"Benefits of RNAi classifiers",value:0.571}, | ||
{axis:"Benefits of anticancer E. coli",value:0.2891}, | {axis:"Benefits of anticancer E. coli",value:0.2891}, | ||
− | {axis:"Public | + | {axis:"Public concern",value:0.656} |
],[//Uncertainty | ],[//Uncertainty | ||
{axis:"Q1",value:0.525}, | {axis:"Q1",value:0.525}, |
Revision as of 00:30, 1 November 2017